Sarepta Therapeutics to Present at Three Upcoming Investor Conferences

August 24, 2017 at 8:30 AM EDT

CAMBRIDGE, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management will present at the following upcoming investor conferences.

  • Baird 2017 Global Healthcare Conference on September 7, 2017 at 11:25 a.m. ET. The fireside chat will be held at the InterContinental New York Barclay Hotel in New York.
     
  • Morgan Stanley 2017 Global Healthcare Conference on September 11, 2017 at 10:30 a.m. ET. The fireside chat will be held at the Grand Hyatt Hotel in New York.
     
  • LEERINK Partners Roundtable – Rare Disease on September 27, 2017 at 10:00 a.m. ET. The fireside chat will be held at the Lotte New York Palace Hotel in New York.

The presentations will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us. 

Source: Sarepta Therapeutics, Inc.

 

Media and Investors:
Sarepta Therapeutics, Inc.Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O GroupBrian Reid, 212-257-6725
breid@w2ogroup.com

Primary Logo

 

Sarepta Therapeutics